Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
This study will examine the synaptotrophic effects of psilocybin among medically healthy, detoxified OUD subjects. Eligible OUD participants will undergo pre- and post- psilocybin administration PET scans with the \[11C\]-UCB-J radiotracer while inpatient.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 21
Maximum Age: 55
Healthy Volunteers: f
View:
• Voluntary, written, informed consent;
• Physically healthy by medical history, physical, neurological, ECG, and laboratory examinations;
• DSM-5 criteria for Opioid Use Disorder;
• Documented evidence (by urine toxicology) of opioid use (upon screening);
• Inpatient verified \> 1 week of abstinence;
• For females, a negative serum pregnancy (beta-HCG) test.
Locations
United States
Connecticut
Yale University
RECRUITING
New Haven
Contact Information
Primary
Gustavo Angarita, MD, MHS
gustavo.angarita@yale.edu
(203) 974-7536
Time Frame
Start Date: 2025-05-28
Estimated Completion Date: 2027-01
Participants
Target number of participants: 12
Treatments
Experimental: Current OUD diagnosis + psilocybin
All participants will receive a \[11C\]-UCB-J PET scan and fMRI with in 1-2 weeks pre and post treatment with one dose of Psilocybin. Intravenous lines will be used for phlebotomy and administration of the \[11C\]-UCB-J radiotracer. On the PET scanning day, a radial arterial catheter may be inserted.
Related Therapeutic Areas
Sponsors
Collaborators: National Institute on Drug Abuse (NIDA)
Leads: Yale University